Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.

Our strategy is to become a fully integrated pharmaceutical company focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases. This strategy includes advancing our product candidates through clinical development to approvals in the U.S., optimizing the development through partnerships, maximizing the value of ZERVIATE through collaborations and expanding our product candidate pipeline through internal research efforts and possible in-licensing activities or acquisitions of additional ophthalmic product candidates or products.

Our ophthalmic pipeline includes three programs in development, research programs which could provide future product candidates and two U.S. Food and Drug Administration (FDA) approved products.

  • NCX 470, a novel, second-generation nitric oxide (NO)-donating bimatoprost analog, in development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. Top-line results from the Dolomites Phase 2 clinical trial demonstrated statistical superiority to latanoprost 0.005%, the U.S. market leader in prostaglandin analog prescriptions. A Phase 3 clinical program is expected to be initiated in Q2 2020 with the 0.065% and 0.1% doses of NCX 470 against a prostaglandin analog, pending the end-of-Phase 2 meeting with the U.S. FDA early in 2020. NCX 470 has been exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese market.
  • NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals, in development for patients with acute exacerbations of blepharitis. NCX 4251 is currently in a Phase 2 clinical study with top-line results expected in December 2019. It has been exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese market.
  • NCX 4280 (formerly AC-120), an ophthalmic solution in development for lid swelling or morning eye congestion. NCX 4280 is currently in an exploratory Phase 2 clinical program led by exclusive worldwide licensee ORA Inc.
    Our pipeline also includes research programs on novel future generation NO donors, including NO-donating phosphodiesterase-5 (PDE5) inhibitors (fully Nicox-owned) and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Cyclerion Therapeutics).

In addition, we have two ophthalmology products that have been approved by the U.S. FDA.

  • VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, indicated for the lowering of IOP in patients with open angle glaucoma or ocular hypertension, is exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and has been commercialized in the United States since December 2017. It has also been approved in Canada and is commercialized there.
  • ZERVIATE™ (cetirizine ophthalmic solution), 0.24% (formerly AC-170), indicated for the treatment of ocular itching associated with allergic conjunctivitis, has been exclusively licensed in the United States to Eyevance Pharmaceuticals and its commercial launch in the U.S. is planned by Eyevance in H1 2020. ZERVIATE has been also exclusively licensed for development and commercialization to Ocumension Therapeutics in the Chinese market as well as to Samil Pharmaceutical in South Korea.

Ophthalmology market

In 2018, the worldwide market for ophthalmic drugs reached $19.9 billion and has grown at a rate of 4% annually since 2014. Worldwide sales of treatments targeting glaucoma were $5.4 billion, representing 27% of the worldwide market.

Reference

IQVIA™ Analytics Link

Ophthalmic Partnerships

All information on partnerships signed by Nicox can be found in the section Overview of the activities of the Document de reference and the subsequent press releases.

Leadership team

Nicox is led by a team of experienced professionals whose combined expertise covers research, clinical development, regulatory interactions, finance, business and corporate development, alliance management and communication. This experience was acquired in leading pharmaceutical and biotech companies. The team includes Michele Garufi, one of Nicox’s co-founders.

Executive team
Consultant
Board of directors

Nicox is proud to present its Board of Directors, whose members are highly experienced in the pharmaceutical and biotech industry.

Glaucoma Clinical Advisory Board

The Glaucoma clinical advisory board is composed of key clinical investigators and opinion leaders in the field to support and guide the development of its innovative nitric oxide (NO)-donating compounds as potential intraocular pressure (IOP)-lowering drugs.